AVEO AVEO Pharmaceuticals Inc.

0.96
-0.05  -5%
Previous Close 1.01
Open 0.98
Price To Book -4.78
Market Cap 132814825
Shares 139,000,340
Volume 3,214,619
Short Ratio
Av. Daily Volume 9,081,602

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation announced December 7, 2017.
Ficlatuzumab and cetuximab
Head and neck squamous cell carcinoma (HNSCC)
Phase 2 data at ESMO 2018 noted 56% ORR.
Tivozanib + Opdivo
Renal cell cancer (RCC)
Announced September 12, 2016 that its Phase 2 trial has been discontinued
Ficlatuzumab
EGFR-mutated Non-small cell lung cancer (NSCLC)
Noted January 31, 2019 that FDA recommended against filing an NDA with current OS data. Additional interim OS analysis due August 2019 with further OS data 4Q 2019.
TIVO-3 - tivozanib
Third line treatment of patients with renal cell cancer
Phase 1b poster presented at AACR April 1, 2019. 9/17 CRs.
Ficlatuzumab and cytarabine
Acute myeloid leukemia (AML)

Latest News

  1. FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of AVEO, SYNH and INGN
  2. FINAL DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  3. SHAREHOLDER ALERT: CORT AVEO MBT ARA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
  4. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aveo Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - AVEO
  5. The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AVEO, CTL and WSR
  6. APR 26 DEADLINE NOTICE: Pawar Law Group Announces a Securities Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. – AVEO
  7. IMPORTANT DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  8. CLASS ACTION UPDATE for CORT, AVEO, DPLO and MBT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  9. AVEO Pharmaceuticals Down More Than 40% in 90 Days: Here's Why
  10. Will AVEO Pharmaceuticals Continue to Surge Higher?
  11. FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of AVEO, AMRN and CVS
  12. INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  13. CLASS ACTION UPDATE for AVEO, CAG and WTW: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  14. SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  15. The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AVEO, DPLO, UMC and NIO
  16. Class Action Deadline CAG, DPLO & AVEO Bronstein, Gewirtz & Grossman, LLC
  17. CLASS ACTION UPDATE for AVEO, DPLO and VNDA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  18. AVEO Pharmaceuticals (AVEO) Dips More Than Broader Markets: What You Should Know
  19. AVEO CLASS ACTION ALERT: Rosen Law Firm Reminds AVEO Pharmaceuticals, Inc. Investors of Important April 26th Deadline in Securities Class Action Lawsuit; Encourages Investors With Losses in Excess of $100K to Contact the Firm – AVEO